Treatment Sequencing in Myelofibrosis

Opinion
Video

Dr Oh provides clinical insights on sequencing therapies for patients with myelofibrosis and discusses the sequential use of JAK inhibitors.

Case: A 63-Year-Old Man with Myelofibrosis

Clinical Presentation:

  • A 63-year-old man recently diagnosed with primary MF and initiated on 10 mg BID ruxolitinib.
  • PMH: type 2 diabetes, hypercholesteremia, and hypertension, squamous cell carcinoma (SCC)

Follow up and Clinical Workup at 3 Months:

  • Exam: night sweats improved.
  • Labs: Hb 7.8 g/dL; Plt 80 x 109/L (previously 135k) stabilized.
  • Some spleen reduction.
  • Patient receives ~1 unit RBC per month.

Follow up and Clinical Workup at 6 Months:

  • Patient reports complaints of fatigue and abdominal pain.
  • Labs: Plt 55 x 109/L; Hgb 6.8 g/dL
  • Patient now receives 2 units RBC per month.
  • Experienced recurrence of SCC.
Related Videos
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Prithviraj Bose, MD, an expert on myelofibrosis
Prithviraj Bose, MD, an expert on myelofibrosis
Related Content
Gene Variant Raises ALL Risk in Hispanic/Latino Children

Gene Variant Raises ALL Risk in Hispanic/Latino Children

April 6th 2024
Article

Adam de Smith, PhD, discussed findings from a study investigating a genetic variant that increases the risk of acute lymphoblastic leukemia in Hispanic/Latino pediatric patients. 

Read More

Examining Efficacy, Toxicity, and Cost-Effectiveness of Myeloma Therapies

Examining Efficacy, Toxicity, and Cost-Effectiveness of Myeloma Therapies

April 1st 2024
Article

In an interview with Targeted Oncology, Doris Hansen, MD, delved into the background, methods, design, and results from 3 recent myeloma studies.

Read More

Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers

Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers

March 21st 2024
Article

During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.

Read More

Addressing MDS Treatment Gap Post Hypomethylating Failure

Addressing MDS Treatment Gap Post Hypomethylating Failure

March 21st 2024
Article

The frontline standard-of-care regimen for patients with higher-risk MDS and some with lower-risk MDS remain hypomethylating agents, such as azacitidine, decitabine, and decitabine/cedazuridine.

Read More

FDA Lifts Clinical Hold on Trial of NX-2127 in B-Cell Malignancies

FDA Lifts Clinical Hold on Trial of NX-2127 in B-Cell Malignancies

March 11th 2024
Article

Following changes to the manufacturing process, the phase 1 study of NX-2127 in B-cell malignancies has been cleared to continue by the FDA.

Read More

GemCloBu: A New Conditioning Regimen for Aggressive Lymphomas

GemCloBu: A New Conditioning Regimen for Aggressive Lymphomas

March 9th 2024
Article

Jeremy Ramdial, MD, discussed a phase 1/2 study investigating the GemCloBu conditioning regimen for stem cell transplants in aggressive lymphomas.

Read More